Prof. Phan Toan Thang's current roles
Founding director and Group Chief Scientific Officer of CRC. Associate Professor of Surgery at the National University of Singapore and lead of a wound healing and stem cell research group.
Every paper, patent, trial and regulatory notice behind the stem cell technology our programs use, each linked to its original source. Records are listed as they are, with no efficacy claims.
Umbilical cord lining stem cell research by Prof. Phan Toan Thang's team in Singapore and CellResearch Corporation (CRC), listed from the original papers, patents, trial registries and regulatory notices. Every item links to its source.
As of 2026-11-16 · Sources: PubMed (NCBI), Google Patents, ClinicalTrials.gov, CRC website, press · Patent status as shown on Google Patents
Team of Assoc. Prof. Phan Toan Thang, Department of Surgery, National University of Singapore. Public papers, patents and trials.
Public recordCo-founded by Prof. Phan, who serves as founding director and Group CSO. Holds the cord lining stem cell patents.
Public recordCellumigen, our founding partner, runs stem cell programs based on this line of technology at clinics in Hanoi and Johor Bahru.
Partner-providedOpens the way to programs through a shared membership tier and a public ledger.
PlannedFounding director and Group Chief Scientific Officer of CRC. Associate Professor of Surgery at the National University of Singapore and lead of a wound healing and stem cell research group.
Authors include CRC staff (conflict of interest declared).
Case series on a topical product made from red deer (not human) cord lining stem cell conditioned media (PTT-6). No control group. CRC supplied the product (conflict of interest declared).
Published results of the phase 1 study run under an FDA IND. No serious adverse events or anti-HLA antibodies were reported in the 9 participants who completed it. A small uncontrolled safety study, not evidence of efficacy. CRC co-founders are authors (conflict of interest declared).
Authors include CRC staff (conflict of interest declared).
Authors include CRC staff (conflict of interest declared).
Authors include CRC staff (conflict of interest declared).
Diabetic foot specialists David Armstrong and Andrew Boulton, and Apligraf inventor Paul Kemp, joined in 2022.
Pharmaceutical company Adalvo announced the phase 1 results, naming CRC as a partner. Terms were not disclosed.
A company status that reduces regulatory fees. Not a product approval. Based on company press releases.
Granted to CorLiCyte for diabetic foot ulcers under the UK's Innovative Licensing and Access Pathway (ILAP). A development-stage designation, not an approval.
CorLiCyte master cell banks are produced under cGMP by ClinImmune Labs at the University of Colorado. The Singapore lab handles quality and biomarker testing.
Single-site, open-label, dose-escalation safety study of cord lining MSCs (CorLiCyte) in chronic diabetic foot ulcers at the University of Colorado Anschutz. Completed in 2023.
Distribution partnership covering China, Hong Kong, Thailand, Malaysia, the Philippines and Indonesia. Based on company press releases.
The Investigational New Drug application for CorLiCyte in diabetic foot ulcers was cleared. It allows human trials to begin and is not a marketing approval.
Began as a cord lining banking partnership. Cordlife invested a further S$8.4 million in February 2016.
Research and services agreement with the University of Colorado School of Medicine (2015), and expanded US cord tissue banking with CariCord (2016).
Vietnamese pharmaceutical company Mekophar licensed the cord lining stem cell extraction technology and set up the MekoStem stem cell bank (operating since 2009).
Co-founded by Phan Toan Thang (Group CSO), Gavin Tan (Group CEO) and Ivor Lim (CMO).
No records match.
Patents grouped by shared priority
| Family | Priority | Subject | Granted / total | Granted in |
|---|---|---|---|---|
| F01 | 2004-08-16 | Isolation, culture and uses of epithelial and mesenchymal stem/progenitor cells from the umbilical cord amniotic membrane (root family) | 22 / 26 | AU, BR, CA, CN, EP, GB, HK, JP, KR, MY, NZ, RU, TW, US, ZA |
| F02 | 2005-10-21 | Uses of cord amniotic membrane stem cells and cells derived from them (skin equivalents, chondrocytes, insulin-producing cells, cosmetic uses) | 8 / 10 | CN, EP, HK, US |
| F03 | 2015-12-14 | Generating transgene-carrying stem cells (with SingHealth) | 0 / 1 | - |
| F04 | 2016-10-05 | Isolating cord lining MSCs with a defined culture medium; high-purity population (CD73, CD90, CD105 at 97% or more) | 19 / 23 | AU, BR, CN, EP, HK, IL, JP, KR, MY, NZ, SA, TW, US, ZA |
| F05 | 2018-04-06 | Transgene-carrying cells from high-purity cord lining MSCs | 0 / 1 | - |
| F06 | 2018-04-09 | Transport solution (e.g. Trolox) for shipping MSCs and applying them to wounds (with the University of Colorado) | 5 / 6 | AU, JP, US |
| F07 | 2018-04-09 | Cell culture medium for shipping MSCs and applying them to wounds | 0 / 1 | - |
| F08 | 2018-04-12 | Culture conditions that induce or improve the wound-healing properties of MSCs | 7 / 10 | AU, CN, JP, TW, US, ZA |
| F09 | 2019-10-08 | Storage and transport formulation for MSCs (with the University of Colorado) | 3 / 6 | AU, CN, JP |
| F10 | 2019-10-08 | Potency assay for the wound-healing activity of MSCs | 4 / 6 | CN, JP, US, ZA |
| F11 | 2020-07-20 | iPS cells derived from cord lining stem cells (with SingHealth) | 1 / 3 | JP |
| F12 | 2022-01-27 | Differentiating iPS cells into retinal pigment epithelium (with A*STAR and SingHealth) | 0 / 2 | - |
| F13 | 2022-11-17 | Cord MSC conditioned medium (secretome) for hair growth and regeneration | 0 / 5 | - |
| F14 | 2022-12-09 | Cord lining MSC conditioned medium (secretome) for healing damaged skin and preventing recurrence | 0 / 5 | - |
The papers and trials here describe the cells, conditions and subjects each study covered. They do not describe outcomes of using the Cellumium network or any partner program.
Of the 37 papers listed, 2 involve human participants. Each item states its study type.
The US phase 1 study (9 completers) was a small uncontrolled safety study. The FDA IND and the UK MHRA designation are development-stage steps, not product approvals.
Papers on CRC products with CRC-affiliated authors are marked with a conflict of interest note. Patent status (active or expired) follows Google Patents.
This page lists public records and makes no medical efficacy claims. It is not medical advice or a diagnosis.